MX376193B - Compuestos para tratar el cancer cerebral. - Google Patents

Compuestos para tratar el cancer cerebral.

Info

Publication number
MX376193B
MX376193B MX2016015436A MX2016015436A MX376193B MX 376193 B MX376193 B MX 376193B MX 2016015436 A MX2016015436 A MX 2016015436A MX 2016015436 A MX2016015436 A MX 2016015436A MX 376193 B MX376193 B MX 376193B
Authority
MX
Mexico
Prior art keywords
brain cancer
compounds
treat brain
brain
patient
Prior art date
Application number
MX2016015436A
Other languages
English (en)
Other versions
MX2016015436A (es
Inventor
Claudio Festuccia
Thomas Mehrling
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MX2016015436A publication Critical patent/MX2016015436A/es
Publication of MX376193B publication Critical patent/MX376193B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporciona un compuesto de fórmula I o una sal farmacéuticamente aceptable del mismo: para uso en el tratamiento de un cáncer cerebral seleccionado de un tumor astrocítico cerebral positivo a MGMT, un cáncer de cerebro metastásico y un linfoma de CNS primario y un método para tratar dichos cánceres cerebrales en un paciente en necesidad del mismo que comprende administrar al paciente dicho compuesto de fórmula I o una sal farmacológicamente aceptable del mismo.
MX2016015436A 2014-05-28 2015-03-26 Compuestos para tratar el cancer cerebral. MX376193B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1409471.8A GB201409471D0 (en) 2014-05-28 2014-05-28 Pharmaceutical composition
PCT/EP2015/056667 WO2015180865A1 (en) 2014-05-28 2015-03-26 Compounds for treating brain cancer

Publications (2)

Publication Number Publication Date
MX2016015436A MX2016015436A (es) 2017-07-04
MX376193B true MX376193B (es) 2025-03-07

Family

ID=51177574

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016015436A MX376193B (es) 2014-05-28 2015-03-26 Compuestos para tratar el cancer cerebral.
MX2016015434A MX382162B (es) 2014-05-28 2015-05-26 Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016015434A MX382162B (es) 2014-05-28 2015-05-26 Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.

Country Status (22)

Country Link
US (8) US11419853B2 (es)
EP (4) EP3998068A1 (es)
JP (3) JP6553092B2 (es)
KR (2) KR102383794B1 (es)
CN (3) CN106659712A (es)
AU (2) AU2015266342B2 (es)
BR (2) BR112016027048B1 (es)
CA (2) CA2950374C (es)
DK (1) DK3148529T3 (es)
EA (2) EA037057B1 (es)
ES (2) ES2897727T3 (es)
GB (1) GB201409471D0 (es)
IL (2) IL249231B (es)
MX (2) MX376193B (es)
NZ (1) NZ725595A (es)
PH (2) PH12016502354A1 (es)
PT (1) PT3148529T (es)
SG (4) SG10201810397SA (es)
TW (1) TWI724990B (es)
UA (2) UA121311C2 (es)
WO (2) WO2015180865A1 (es)
ZA (2) ZA201607384B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201601773D0 (en) 2016-02-01 2016-03-16 Renishaw Plc Method
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11266631B2 (en) 2016-10-11 2022-03-08 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
TWI651088B (zh) 2017-03-23 2019-02-21 國立東華大學 用於治療癌症的Scalarane二倍半萜類、醫藥組合物及拓樸異構酶II與 Hsp90抑制劑及其用途與製備方法
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) * 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) * 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
CA3075714A1 (en) * 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
AU2019400983B2 (en) * 2018-12-18 2025-07-03 Mundipharma International Corporation Limited Compounds for treating multiple myeloma
CN112023022A (zh) * 2020-10-20 2020-12-04 澳门大学 卡非佐米在制备治疗抗药肿瘤的药物中的新的应用
JP7600020B2 (ja) 2021-03-31 2024-12-16 株式会社小糸製作所 画像投影装置

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE34727C (de) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Verfahren zur direkten Gewinnung metallischen Bleis
DD34727A1 (de) 1963-12-21 1964-12-28 Dietrich Krebs Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5882941A (en) 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6133248A (en) 1997-06-13 2000-10-17 Cydex, Inc. Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
WO2002004009A2 (en) 2000-07-12 2002-01-17 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP2083005A1 (en) 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
CN1764648A (zh) 2003-01-13 2006-04-26 安斯泰来制药有限公司 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物
JP4790594B2 (ja) 2003-02-25 2011-10-12 トポターゲット ユーケー リミテッド Ｈｄａｃインヒビターとしての、二環式ヘテロアリール基を含むヒドロキサム酸化合物
US20060270730A1 (en) 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US8227636B2 (en) 2004-04-05 2012-07-24 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP1901729B1 (en) 2005-05-13 2012-01-25 TopoTarget UK Limited Pharmaceutical formulations of hdac inhibitors
US7399956B2 (en) 2005-11-28 2008-07-15 Avago Technologies Ecbuip Pte Ltd Optical encoder with sinusoidal photodetector output signal
MX2009004214A (es) 2006-10-20 2009-05-11 Icos Corp Composiciones de inhibidores de chk1.
GB0621160D0 (en) 2006-10-24 2006-12-06 Imp College Innovations Ltd Compounds and uses thereof
NZ595522A (en) 2006-11-20 2013-04-26 Cephalon Inc Method of radio-sensitizing tumors using a radio-sensitizing agent
JP2010512407A (ja) * 2006-12-11 2010-04-22 ジェネンテック インコーポレイテッド 新生物を処置するための組成物および方法
CN101084876A (zh) 2007-07-11 2007-12-12 济南康泉医药科技有限公司 一种含苯达莫司汀的抗癌组合物
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
US20090131367A1 (en) 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
WO2009100045A1 (en) 2008-02-04 2009-08-13 Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
EP2889029A1 (en) 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
JP5773874B2 (ja) 2008-10-08 2015-09-02 セファロン、インク． ベンダムスチンの調製方法
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
RS54192B1 (sr) 2009-01-23 2015-12-31 Euro-Celtique S.A. Derivati hidroksamske kiseline
CA2753641C (en) 2009-02-25 2014-09-16 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
WO2011017448A1 (en) 2009-08-05 2011-02-10 The Trustees Of The University Of Pennsylvania Use of histone deacetylase inhibitors for treatment of autoimmune diseases
CN101928234B (zh) 2010-01-15 2012-12-12 北京欧凯纳斯科技有限公司 6/7-（杂）芳基-n-羟基己/庚酰胺化合物及其制备方法
EP2558866B1 (en) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
ES2605586T3 (es) 2010-04-16 2017-03-15 Cellact Pharma Gmbh Análogos de etopósido para el tratamiento de tumores metastásicos
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
US8748470B2 (en) 2011-03-17 2014-06-10 The University Of Chicago Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
SG2014014419A (en) 2011-09-13 2014-07-30 Pharmacyclics Inc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
CN102993102B (zh) 2011-09-16 2016-08-24 杭州民生药业有限公司 [1-甲基-2-(7’-庚异羟肟酸基)-5-n，n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法
MX346432B (es) * 2011-09-18 2017-03-21 Euro-Celtique S A * Composiciones farmaceuticas.
US8962855B2 (en) 2011-09-28 2015-02-24 Purdue Pharmaceutical Products, L.P. Nitrogen mustard derivatives
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
JP6525474B2 (ja) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
NZ630314A (en) 2014-02-18 2016-03-31 Celgene Corp Combination therapy for hematological malignancies
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
JP2017537164A (ja) 2014-12-05 2017-12-14 ユニヴァーシティ・オブ・モデナ・アンド・レッジョ・エミリア リンパ腫の治療に使用されるヒストン脱アセチル化酵素阻害剤とベンダムスチンとの組み合わせ
JP2016109634A (ja) 2014-12-09 2016-06-20 株式会社安川電機 エンコーダ及びエンコーダ付きモータ
CN106580971B (zh) 2015-10-20 2019-11-12 杭州梯诺医药科技有限公司 一种药物组合物及其制备方法
US11266631B2 (en) 2016-10-11 2022-03-08 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
US20180098969A1 (en) 2016-10-11 2018-04-12 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
AU2019400983B2 (en) 2018-12-18 2025-07-03 Mundipharma International Corporation Limited Compounds for treating multiple myeloma
US20240252472A1 (en) 2023-01-25 2024-08-01 Purdue Pharma L.P. Combinations for treating cancer

Also Published As

Publication number Publication date
US20230241033A1 (en) 2023-08-03
MX2016015434A (es) 2017-06-23
CN106659712A (zh) 2017-05-10
IL249229B (en) 2020-07-30
SG11201609360WA (en) 2016-12-29
IL249231A0 (en) 2017-02-28
BR112016027041B1 (pt) 2023-03-21
CA2950338A1 (en) 2015-12-03
IL249231B (en) 2022-09-01
ES2949222T3 (es) 2023-09-26
PH12016502355B1 (en) 2022-04-01
NZ725595A (en) 2023-03-31
IL249229A0 (en) 2017-02-28
WO2015180865A1 (en) 2015-12-03
US12048688B2 (en) 2024-07-30
US12403130B2 (en) 2025-09-02
US11419853B2 (en) 2022-08-23
ES2897727T3 (es) 2022-03-02
EP3148536B1 (en) 2023-06-28
BR112016027041A8 (pt) 2021-07-20
US20210346351A1 (en) 2021-11-11
EA201692480A1 (ru) 2017-04-28
US11559516B2 (en) 2023-01-24
CA2950338C (en) 2024-01-16
ZA201607384B (en) 2021-06-30
EP3148536A1 (en) 2017-04-05
KR102383794B1 (ko) 2022-04-06
BR112016027048A2 (pt) 2017-08-15
CA2950374C (en) 2023-10-03
EP3148529B1 (en) 2021-10-20
TW201625240A (zh) 2016-07-16
US20180369204A1 (en) 2018-12-27
MX382162B (es) 2025-03-11
KR20170005106A (ko) 2017-01-11
EA035658B1 (ru) 2020-07-23
EP3148536C0 (en) 2023-06-28
EA037057B1 (ru) 2021-01-29
EP3957307A1 (en) 2022-02-23
AU2015266342B2 (en) 2020-07-02
TWI724990B (zh) 2021-04-21
JP6553092B2 (ja) 2019-07-31
US20250009715A1 (en) 2025-01-09
AU2015266052B2 (en) 2020-07-09
US20170151218A1 (en) 2017-06-01
CA2950374A1 (en) 2015-12-03
JP2017516781A (ja) 2017-06-22
DK3148529T3 (da) 2021-12-13
JP2017518291A (ja) 2017-07-06
US20170189382A1 (en) 2017-07-06
PH12016502354A1 (en) 2017-02-13
SG11201609365UA (en) 2016-12-29
BR112016027048B1 (pt) 2023-01-03
US20190343807A1 (en) 2019-11-14
EP3998068A1 (en) 2022-05-18
CN106470696B (zh) 2021-04-27
JP7274450B2 (ja) 2023-05-16
SG10201810401RA (en) 2018-12-28
JP2021059579A (ja) 2021-04-15
EA201692472A1 (ru) 2017-05-31
BR112016027048A8 (pt) 2021-07-20
AU2015266052A1 (en) 2016-11-10
EP3148529A1 (en) 2017-04-05
US20230049350A1 (en) 2023-02-16
MX2016015436A (es) 2017-07-04
AU2015266342A1 (en) 2016-11-10
CN111467339A (zh) 2020-07-31
KR102451701B1 (ko) 2022-10-06
PT3148529T (pt) 2021-11-17
BR112016027041A2 (pt) 2017-08-15
WO2015181156A1 (en) 2015-12-03
US10406138B2 (en) 2019-09-10
SG10201810397SA (en) 2018-12-28
CN106470696A (zh) 2017-03-01
ZA201607488B (en) 2025-05-28
PH12016502355A1 (en) 2017-02-13
UA122207C2 (uk) 2020-10-12
US12370177B2 (en) 2025-07-29
UA121311C2 (uk) 2020-05-12
KR20170012372A (ko) 2017-02-02
GB201409471D0 (en) 2014-07-09

Similar Documents

Publication Publication Date Title
MX376193B (es) Compuestos para tratar el cancer cerebral.
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
CL2017002242A1 (es) Método para tratar un tumor cerebral
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
MX384403B (es) Terapia de combinación para el tratamiento del cáncer.
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
PH12017500493A1 (en) Combination therapy
PH12017500215A1 (en) Protein kinase c inhibitors and methods of their use
EA201791736A1 (ru) Комбинированная терапия для лечения рака
MX368286B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
NZ732511A (en) Small molecule inhibitors of egfr and pi3k
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
MX388722B (es) Compuestos para tratar el cancer de ovario.
MX375716B (es) Método para tratar adenocarcinoma de pulmón.
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
EA201692155A1 (ru) МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
EA201892311A1 (ru) Производные 2-анилинопиримидина в качестве терапевтических агентов для лечения рака мозга
EA201891008A3 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
NZ742470A (en) Combination therapy for cancer
EA201990411A1 (ru) Способы лечения рака предстательной железы
EA201492019A1 (ru) Способы лечения рака с помощью липопептидов

Legal Events

Date Code Title Description
FG Grant or registration